Hims & Hers Health (NYSE:HIMS) Sees Unusually-High Trading Volume - Still a Buy?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares saw an uptick in trading volume on Friday . 5,570,696 shares changed hands during mid-day trading, a decline of 38% from the previous session's volume of 8,949,964 shares.The stock last traded at $25.99 and had previously closed at $27.94.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HIMS. Morgan Stanley began coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $42.00 price target on the stock. BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price target on the stock. Piper Sandler lifted their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a "neutral" rating in a research note on Monday, January 6th. Citigroup cut shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and lifted their price target for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Hold" and a consensus target price of $25.13.

Hims & Hers Health Stock Performance

The firm's 50-day moving average price is $27.68 and its two-hundred day moving average price is $21.85. The stock has a market cap of $6.07 billion, a price-to-earnings ratio of 63.19 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the business's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now directly owns 184,947 shares in the company, valued at $6,206,821.32. This represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 2,339 shares of the business's stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the sale, the insider now owns 169,935 shares in the company, valued at $3,935,694.60. This trade represents a 1.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,080,208 shares of company stock worth $29,106,823. Company insiders own 17.71% of the company's stock.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of HIMS. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares during the period. GAMMA Investing LLC increased its stake in shares of Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock worth $54,000 after buying an additional 2,152 shares during the period. Quest Partners LLC increased its stake in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company's stock worth $81,000 after buying an additional 807 shares during the period. CWM LLC increased its stake in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after buying an additional 1,054 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in shares of Hims & Hers Health by 115.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company's stock worth $110,000 after buying an additional 2,442 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.